BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30634399)

  • 1. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
    Lang L; Teng Y
    Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
    Gao L; Shay C; Lv F; Wang X; Teng Y
    Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
    Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
    Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making way for suppressing the FGF19/FGFR4 axis in cancer.
    Prieto-Dominguez N; Shull AY; Teng Y
    Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
    Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
    Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
    Hu L; Cong L
    Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
    Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
    Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of fibroblast growth factor receptor 4 in cancer.
    Tang S; Hao Y; Yuan Y; Liu R; Chen Q
    Cancer Sci; 2018 Oct; 109(10):3024-3031. PubMed ID: 30070748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
    Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
    Levine KM; Ding K; Chen L; Oesterreich S
    Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
    Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
    Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
    Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
    J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?
    Heinzle C; Erdem Z; Paur J; Grasl-Kraupp B; Holzmann K; Grusch M; Berger W; Marian B
    Curr Pharm Des; 2014; 20(17):2881-98. PubMed ID: 23944363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.